Abstract #1127

Longitudinal & quantitative 3D-R2* MRI validates methimazole-enhanced intranasal delivery of labeled neural stems cells for treatment of glioblastoma.

Daniele Procissi¹, Nicola Bertolino², Drew Spencer³, Dou Yu ³, Katarzyna C Pituch³, Maciej S Lesniak³, and Irina V Balyasnikova³

¹Radiology & Biomedical Engineering, Northwestern University, Chicago, IL, United States, ²Radiology, Northwestern University, Chicago, IL, United States, ³Neurosurgery, Northwestern University, Chicago, IL, United States

Longitudinal and quantitative 3D-R*₂MRI provides a unique platform for tracking labeled cells in vivo, across subjects and time-points following treatment. In this study we use this approach to demonstrate how FDA approved methimazole can enhance intranasal delivery and accumulation of labeled and therapeutically enhanced neural stem cells in glioma xenografts. 3D rendering of the high resolution quantitative maps across different sessions enhances visualization of the NSC accumulation and provides a unique tool to track the homing-pathway of the stem cells. Results were confirmed by survival data for different groups with the Met+NSC treated group exhibiting increased survival trends.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.